Get the Stockscreener App
9.97
2.06%
-0.21
After Hours:
10.00
0.03
+0.30%
Korro Bio Inc stock is traded at $9.97, with a volume of 138.44K.
It is down -2.06% in the last 24 hours and down -30.72% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$10.18
Open:
$10.28
24h Volume:
138.44K
Relative Volume:
0.79
Market Cap:
$143.79M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-0.7988
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
-13.00%
1M Performance:
-30.72%
6M Performance:
+60.29%
1Y Performance:
-34.02%
1-Day Range:
$9.70
$10.71
1-Week Range:
$9.70
$11.56
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
9.97 | 146.82M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21 - Moomoo
Citigroup Initiates Korro Bio at Buy With $21 Price Target - marketscreener.com
Lynx1 Capital Management LP's Korro Bio Inc(KRRO) Holding History - GuruFocus
Should You Sell Korro Bio (KRRO) After -8.12% Drop? 2026-05-15Cash Flow - newser.com
Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage - Traders Union
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Korro Bio hire gets option for 3,000 shares at $11.20 - Stock Titan
Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro announces oversubscribed $85 million private placement - MSN
Number of shareholders of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Korro Bio (NASDAQ:KRRO) Announces Quarterly Earnings Results - MarketBeat
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
JonesTrading Upgrades Korro Bio(KRRO.US) to Buy Rating, Announces Target Price $23 - Moomoo
Jones Trading upgrades Korro Bio stock rating on AATD program potential By Investing.com - Investing.com South Africa
Jones Trading upgrades Korro Bio stock rating on AATD program potential - Investing.com Nigeria
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korro Bio IncReports No Collaboration Reve - Moomoo
Korro Bio (KRRO) trims R&D spend and boosts cash to $157M - Stock Titan
Korro Bio, Inc. 1Q 2026: Revenue $0M, EPS $(1.69) — 10-Q Summary - TradingView
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Korro raises $85M, targets 2026 filing for rare-disease drug - Stock Titan
Korro Bio (Nasdaq: KRRO) boosts cash to $157M and targets 2026 KRRO-121 filing - Stock Titan
What Korro Bio (KRRO) management is not saying enough about (Technical Strength) 2026-05-06Top Trending Breakouts - newser.com
Korro CEO and top executives line up two investor fireside chats - Stock Titan
Korro to Participate in Upcoming Investor Conferences - marketscreener.com
Korro Bio Inc expected to post a loss of $1.84 a shareEarnings Preview - TradingView
What makes Korro Bio, Inc. (KRRO) a new buy stock - MSN
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock - Yahoo Finance Australia
Raymond James upgrades Korro Bio (KRRO) - MSN
Korro Bio (KRRO) Moat Analysis | Q4 2025: Earnings Beat EstimatesExpert Momentum Signals - Cổng thông tin điện tử tỉnh Lào Cai
KRRO (Korro Bio Inc.) reports smaller than projected Q4 2025 loss, shares rise nearly 7 percent on investor optimism.Hot Market Picks - newser.com
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences - The Manila Times
Korro brings ammonia and liver disease data to 4 spring conferences - Stock Titan
[ARS] Korro Bio, Inc. SEC Filing - Stock Titan
Korro Bio (KRRO) outlines 2026 virtual meeting, director elections and pay vote - Stock Titan
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule - National Today
Latest KRRO NewsKorro to Present at the 42nd Annual J.P. Mo... - Stock Titan
Korro Bio reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Korro Bio hire gets stock option for 15,000 shares under Nasdaq rule - Stock Titan
Block Trades: Does Korro Bio Inc have pricing powerWeekly Investment Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Lynx1 Capital Management LP Increases Stake in Korro Bio Inc - GuruFocus
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):